The expression of DJ-1 was significantly higher in HR+ subtypes patients tumor samples compared to normal counterparts but not in HER2+ or triple-negative breast cancer (TNBC, HR−, and HER2−) subtypes (Figure 2(b)). Here, PARK7 is linked to triple-negative breast carcinoma.